1. Approximately what percent of people with diabetes in the United States (US) have diabetes-related kidney disease?
A. Approximately 10%
B. Approximately 20%
C. Approximately 40%
D. Approximately 80%
2. According to the 2021 American Diabetes Association (ADA) Standards of Medical Care in Diabetes, which medication class is recommended in patients with diabetic kidney disease (DKD) with albuminuria?
A. DPP-4 inhibitor (such as sitagliptin [Januvia])
B. GLP-1 receptor agonist (such as liraglutide [Victoza])
C. Sulfonylurea (such as glimepiride [Amaryl])
D. SGLT2 inhibitor (such as dapagliflozin [Farxiga])
3. A patient with type 2 diabetes (T2D) and chronic kidney disease (CKD) is taking metformin plus an SGLT2 inhibitor but needs another medication to help lower their blood glucose. Which of the following medication classes would be the preferred choice, according to Kidney Disease Improving Global Outcomes (KDIGO)?
A. GLP-1 receptor agonist (such as dulaglutide [Trulicity])
B. Basal insulin (such as insulin glargine [Lantus])
C. Alpha-glucosidase inhibitor (such as acarbose)
D. DPP-4 inhibitor (such as linagliptin [Tradjenta])
4. Keeping the genital area clean and dry is recommended to help avoid which of the following side effects in people taking an SGLT2 inhibitor?
A. Genital mycotic infections (such as yeast infections)
B. Volume depletion and low blood pressure
C. Hypoglycemia (low blood glucose)
D. Diabetic ketoacidosis (DKA)
5. SGLT2 inhibitors are approved for which of the following uses based on improvement in patients in studies?
A. To treat type 2 diabetes (T2D) and improve blood glucose control
B. To improve kidney disease outcomes in patients with T2D
C. To improve heart failure (HF) outcomes
D. All of the above
Evaluation Questions
6. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
7. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
8. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
9. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
10. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
11. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Will the information presented cause you to change your practice?
A. Yes
B. No
18. Are you committed to making these changes?
A. Yes
B. No
19. As a result of this activity, did you learn something new?
A. Yes
B. No
20. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
21. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20